MA42988A - Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide - Google Patents
Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamideInfo
- Publication number
- MA42988A MA42988A MA042988A MA42988A MA42988A MA 42988 A MA42988 A MA 42988A MA 042988 A MA042988 A MA 042988A MA 42988 A MA42988 A MA 42988A MA 42988 A MA42988 A MA 42988A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazolo
- carboxamide
- pyrimidine
- ether derivatives
- spirocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15189600.8A EP3156405A1 (fr) | 2015-10-13 | 2015-10-13 | Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide |
PCT/EP2016/074380 WO2017064082A1 (fr) | 2015-10-13 | 2016-10-12 | Dérivés d'éther cyclique de pyrazolo[1,5-a]pyrimidine-3-carboxyamide |
Publications (2)
Publication Number | Publication Date |
---|---|
MA42988A true MA42988A (fr) | 2021-04-07 |
MA42988B1 MA42988B1 (fr) | 2022-04-29 |
Family
ID=54293164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA42988A MA42988B1 (fr) | 2015-10-13 | 2016-10-12 | Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide |
Country Status (30)
Country | Link |
---|---|
US (5) | US10023575B2 (fr) |
EP (2) | EP3156405A1 (fr) |
JP (1) | JP6626965B2 (fr) |
KR (1) | KR102611558B1 (fr) |
CN (2) | CN114181213A (fr) |
AU (1) | AU2016338602B2 (fr) |
BR (1) | BR112018004347B1 (fr) |
CA (1) | CA3001929C (fr) |
CL (1) | CL2018000856A1 (fr) |
CO (1) | CO2018003756A2 (fr) |
DK (1) | DK3362453T3 (fr) |
EA (1) | EA035350B1 (fr) |
ES (1) | ES2912223T3 (fr) |
HK (1) | HK1254651A1 (fr) |
HR (1) | HRP20220595T1 (fr) |
IL (1) | IL258070B (fr) |
LT (1) | LT3362453T (fr) |
MA (1) | MA42988B1 (fr) |
MX (1) | MX2018004524A (fr) |
MY (1) | MY195169A (fr) |
NZ (1) | NZ740119A (fr) |
PE (2) | PE20181447A1 (fr) |
PH (1) | PH12018500796A1 (fr) |
PL (1) | PL3362453T3 (fr) |
PT (1) | PT3362453T (fr) |
RS (1) | RS63218B1 (fr) |
SA (1) | SA518391334B1 (fr) |
SI (1) | SI3362453T1 (fr) |
UA (1) | UA124576C2 (fr) |
WO (1) | WO2017064082A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3156405A1 (fr) * | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide |
RU2671964C1 (ru) * | 2017-08-30 | 2018-11-08 | Сиа Эволед | Пиразоло[1,5-а]пиримидинкарбоксилаты гадолиния и органические светодиоды на их основе |
US11498928B2 (en) | 2019-01-18 | 2022-11-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic spiroethers as Mcl-1 inhibitors |
CN110339197A (zh) * | 2019-06-24 | 2019-10-18 | 中山大学 | 一种防治血管性痴呆的磷酸二酯酶9a抑制剂的用途 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10108752A1 (de) | 2001-02-23 | 2002-09-05 | Bayer Ag | Neue Substituierte Imidazotriazinone |
CA2494700C (fr) * | 2002-08-26 | 2011-06-28 | Takeda Pharmaceutical Company Limited | Compose modulateur de recepteur de calcium et utilisation associee |
WO2005041957A1 (fr) | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Derives d'oxindole et leur utilisation comme inhibiteurs de la phosphodiesterase de type 2 |
WO2005061497A1 (fr) | 2003-12-16 | 2005-07-07 | Pfizer Products Inc. | Pyrido[2,3-d]pyrimidine-2,4-diamines en tant qu'inhibiteurs de la pde 2 |
EP1548011A1 (fr) | 2003-12-23 | 2005-06-29 | Neuro3D | Dérivés de 1,4-benzodiazépine-2-one comme inhibiteurs de PDE2 phosphodiesterase, leurs préparation et utilisation thérapeutique |
WO2005087751A2 (fr) | 2004-03-09 | 2005-09-22 | Elan Pharmaceuticals, Inc. | Aspartyle a base d'hydroxyethylamine substitue inhibiteurs de la protease |
FR2870539B1 (fr) | 2004-05-19 | 2006-08-04 | Greenpharma Sa Sa | Nouvelles methodes et medicaments |
KR101368093B1 (ko) | 2004-09-02 | 2014-03-14 | 다케다 게엠베하 | 트리아졸로프탈라진 |
AU2006204451C1 (en) | 2005-01-05 | 2012-05-24 | Takeda Gmbh | Triazolophthalazines as PDE2-inhibitors |
EA012505B1 (ru) | 2005-01-05 | 2009-10-30 | Никомед Гмбх | Триазолофталазины в качестве ингибиторов pde-2 |
BRPI0502411A (pt) | 2005-03-31 | 2006-11-28 | Univ Minas Gerais | processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados |
US8188097B2 (en) | 2005-10-21 | 2012-05-29 | Mitsubishi Tanabe Pharma Corporation | Pyrazolo[1,5-A]pyrimidine compounds |
JP4847275B2 (ja) * | 2005-10-21 | 2011-12-28 | 田辺三菱製薬株式会社 | ピラゾロ[1,5−a]ピリミジン化合物 |
CN101296699B (zh) * | 2005-10-21 | 2013-01-02 | 田边三菱制药株式会社 | 吡唑并[1,5-a]嘧啶化合物 |
WO2007121319A2 (fr) | 2006-04-14 | 2007-10-25 | University Of California | Compostions et procédés destinés à déterminer et à prevoir des réponses aux traitements de la dépression et de l'anxiété |
TW201345908A (zh) | 2006-07-05 | 2013-11-16 | Mitsubishi Tanabe Pharma Corp | 吡唑并〔1,5-a〕嘧啶化合物 |
AR061793A1 (es) | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica |
DE102006048693A1 (de) | 2006-10-14 | 2008-04-17 | Bayer Healthcare Ag | Inhibition der PDE2A |
GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
SG194397A1 (en) | 2008-10-31 | 2013-11-29 | Genentech Inc | Pyrazolopyrimidine jak inhibitor compounds and methods |
CA2750935A1 (fr) | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryles et applications associees |
WO2012021615A1 (fr) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Hétéroaryles et utilisations |
US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
BR112013033375B1 (pt) | 2011-06-27 | 2022-05-10 | Janssen Pharmaceutica N.V | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário |
WO2013034761A1 (fr) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Composés de pyridine et leurs utilisations |
US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
WO2014025651A1 (fr) * | 2012-08-06 | 2014-02-13 | Amgen Inc. | Dérivés de chromane en tant qu'inhibiteurs de trpm8 |
JPWO2015012328A1 (ja) | 2013-07-24 | 2017-03-02 | 武田薬品工業株式会社 | 複素環化合物 |
EP3061754A4 (fr) | 2013-10-23 | 2017-03-22 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique |
US9815796B2 (en) | 2013-12-23 | 2017-11-14 | Merck Sharp & Dohme Corp. | Pyrimidone carboxamide compounds as PDE2 inhibitors |
EP3156405A1 (fr) * | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide |
JP2017095366A (ja) * | 2015-11-18 | 2017-06-01 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
-
2015
- 2015-10-13 EP EP15189600.8A patent/EP3156405A1/fr not_active Ceased
-
2016
- 2016-10-12 PL PL16788047.5T patent/PL3362453T3/pl unknown
- 2016-10-12 LT LTEPPCT/EP2016/074380T patent/LT3362453T/lt unknown
- 2016-10-12 EP EP16788047.5A patent/EP3362453B1/fr active Active
- 2016-10-12 UA UAA201804978A patent/UA124576C2/uk unknown
- 2016-10-12 PT PT167880475T patent/PT3362453T/pt unknown
- 2016-10-12 ES ES16788047T patent/ES2912223T3/es active Active
- 2016-10-12 US US15/291,316 patent/US10023575B2/en active Active
- 2016-10-12 BR BR112018004347-8A patent/BR112018004347B1/pt active IP Right Grant
- 2016-10-12 AU AU2016338602A patent/AU2016338602B2/en active Active
- 2016-10-12 MY MYPI2018000484A patent/MY195169A/en unknown
- 2016-10-12 NZ NZ740119A patent/NZ740119A/en unknown
- 2016-10-12 PE PE2018001274A patent/PE20181447A1/es unknown
- 2016-10-12 DK DK16788047.5T patent/DK3362453T3/da active
- 2016-10-12 SI SI201631526T patent/SI3362453T1/sl unknown
- 2016-10-12 RS RS20220468A patent/RS63218B1/sr unknown
- 2016-10-12 KR KR1020187013541A patent/KR102611558B1/ko active IP Right Grant
- 2016-10-12 EA EA201890922A patent/EA035350B1/ru not_active IP Right Cessation
- 2016-10-12 CN CN202111335164.6A patent/CN114181213A/zh active Pending
- 2016-10-12 PE PE2018000540A patent/PE20190778A1/es unknown
- 2016-10-12 HR HRP20220595TT patent/HRP20220595T1/hr unknown
- 2016-10-12 WO PCT/EP2016/074380 patent/WO2017064082A1/fr active Application Filing
- 2016-10-12 CA CA3001929A patent/CA3001929C/fr active Active
- 2016-10-12 MX MX2018004524A patent/MX2018004524A/es active IP Right Grant
- 2016-10-12 CN CN201680059328.8A patent/CN108137602B/zh active Active
- 2016-10-12 JP JP2018518960A patent/JP6626965B2/ja active Active
- 2016-10-12 MA MA42988A patent/MA42988B1/fr unknown
-
2018
- 2018-01-09 US US15/865,695 patent/US10479794B2/en active Active
- 2018-03-13 IL IL258070A patent/IL258070B/en active IP Right Grant
- 2018-04-03 CL CL2018000856A patent/CL2018000856A1/es unknown
- 2018-04-09 CO CONC2018/0003756A patent/CO2018003756A2/es unknown
- 2018-04-11 SA SA518391334A patent/SA518391334B1/ar unknown
- 2018-04-13 PH PH12018500796A patent/PH12018500796A1/en unknown
- 2018-10-24 HK HK18113618.5A patent/HK1254651A1/zh unknown
-
2019
- 2019-10-14 US US16/600,965 patent/US10875867B2/en active Active
-
2020
- 2020-10-20 US US17/075,091 patent/US11691977B2/en active Active
-
2023
- 2023-05-19 US US18/320,264 patent/US20230286993A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52987A (fr) | Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak | |
MA47500A (fr) | Dérivés de pyrrolo [1,2-b]pyridazine | |
HK1256751A1 (zh) | [1,2,4]三唑並[1,5-a]嘧啶-7-基化合物 | |
EP3107914B8 (fr) | Pyrazolo[1,5-a]pyrimidine-5,7-diamines en tant qu'inhibiteurs de cdk et leur utilisation thérapeutique | |
DK3134413T3 (da) | Substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer | |
DK3418281T3 (da) | Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme | |
MA43021A (fr) | Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu'inhibiteurs doubles de dyrk1/clk1 | |
ZA201701814B (en) | Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2 | |
MA42988A (fr) | Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide | |
ZA201605666B (en) | Pyrazolo[1,5-a]pyrimidines as antiviral compounds | |
MA46690A (fr) | Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 | |
TH1601001194A (th) | อนุพันธ์ไตรอะโซโล[4,5-d]ไพริมิดีน ใหม่ | |
TH1601003657A (th) | อนุพันธ์ [1,2,4] ไตรอะโซโล [1,5-a]ไพริมิดีน ดังสารยับยั้งโปรเตียโซมของ โปรโตซัวสำหรับการรักษาของโรคที่เกิดจากปรสิต เช่น โรคลิชมาเนียซิส |